The University of Rochester
Virtual Drug Discovery Center
The goal of the University of Rochester Virtual Drug Discovery Center (UR VDDC) is to accelerate research by investigators at the University of Rochester who are working on new drug discovery.
This site is organized to provide assistance with each step during the drug discovery process, and to provide access to local expertise and investigators who can provide advice and assistance with drug development projects, at all stages, including:
- A directory of faculty with expertise in areas relevant to drug development, including funded research projects
- Target validation and high-throughput screening of molecular libraries
- Medicinal chemistry and structure-activity relationship (SAR) analysis
- Structural determination, molecular modeling, and affinity measurements
- Intellectual property (the invention disclosure and patenting processes)
- Technology development and "gap" funding
- A listing of UR spin-off companies with interests in drug development
- FDA regulatory compliance and filing of an Investigational New Drug application
Press Releases & News Stories:
August 28th, 2011
URMC and Temple University Announce Drug Discovery Partnership
The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.
“This is a perfect marriage of the world class drug discovery and medicinal chemistry programs of Temple University with the strong biomedical expertise of URMC and its faculty,” said Stephen Dewhurst, Ph.D., chair of the URMC Department of Microbiology and Immunology. “I am excited by the opportunities this creates to explore innovative therapeutic approaches and targets.”
August 25th, 2011
"Opposites attract" from Nature.com
by Steve Edelson, Executive Editor
Target rich but chemistry poor, the University of Rochester Medical Center has teamed up with Temple University School of Pharmacy, which has strong chemistry capabilities but lacks targets for compound building. The partners think their approach provides a translational template for midsized research institutions.
SciBX 4(33); doi:10.1038/scibx.2011.923